Company News

MicrosensDx teams up with ProteoGenix on early sepsis detection test

Park member MicrosensDx has partnered with ProteoGenix to advance a new diagnostic test aimed at improving early detection of sepsis.

The collaboration will accelerate development of a novel biomarker-based ELISA test, designed to identify patients at risk of severe sepsis more quickly and accurately. With sepsis causing around 48,000 deaths annually in the UK, earlier diagnosis remains a critical unmet need.

MicrosensDx will draw on ProteoGenix’s antibody expertise as it moves the test towards clinical trials. Simon Walker, CEO of MicrosensDx, said: “We achieved promising results in detecting the oxidised biomarker during 2025, and this has given us the confidence to seek additional investment and begin scaling up in readiness for clinical trials.”

Related stories

Read More

In her final reflection from China, Cambridge Science Park’s Director of External Relations and Innovation, Jane Hutchins, considers the contrast ...

Read More

This year’s Cambridge Science Park Christmas Market on 3 December will help fund something most of us take for granted. ...

Read More

Mursla Bio has added another major accolade to a standout year, being named Best Emerging Biotech Company at the 2026 ...

Want to see your news featured here? Contact the team and let’s spread the word.